Shots:
- The company completes two P-III studies that compares proposed biosimilar Gan & Lee insulin glargine (GL-GLA) to a reference biologic n subjects with type 1 (n=576) and type 2 diabetes mellitus (n=567) for 26wks.
- The focus of the study is to assess the equivalence in treatment-induced (TI) immunogenicity between GL-GLA and the reference biologic using pre-specified similarity margins while the secondary objectives were to assess the equivalence in efficacy and evaluate safety
- Both studies concluded there was equivalent TI immunogenicity with equivalent efficacy outcomes whereas safety endpoints were comparable between GL-GLA and the reference biologic
Click here to read the full press release/ article | Ref: Gan & Lee | Image: WebsEdge
The post Gan & Lee Completes P-III Studies of GL-GLA for Patients with T1D & T2D first appeared on PharmaShots.
